A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval

Overview

Información sobre este estudio

The purpose of this study is to assess the impact of repeating Cologuard testing for colon cancer at 3 year intervals in average risk patients.

Elegibilidad para la participación

Los requisitos de elegibilidad de los participantes incluyen la edad, el sexo, el tipo y el estadio de la enfermedad, y los problemas de salud o tratamientos previos. Las pautas difieren de un estudio a otro e identifican quiénes pueden o no pueden participar. No hay garantía de que cada persona elegible que desee participar en un ensayo se inscribirá. Comunícate con el equipo del estudio para analizar la elegibilidad del estudio y la posible participación.

Inclusion Criteria:

  • Subject has been prescribed Cologuard for colorectal cancer screening
  • Subject is at average risk for development of colorectal cancer
  • Subject is 50 years or older
  • Subject willing and able to sign informed consent

Exclusion Criteria:

  • Subject had a colonoscopy in the previous 9 years
  • Subject has undergone any double-contrast barium enema, virtual (CT-based) colonoscopy, or flexible sigmoidoscopy within the previous (5) years
  • Subject has had a positive fecal occult blood test or FIT within the previous six (6) months
  • Subject has any condition that in the opinion of the investigator should preclude participation in the study (e.g., subject not eligible for a diagnostic colonoscopy)
  • Subject has a history of colorectal cancer or advanced adenoma
  • Subject has a history of aerodigestive tract cancer
  • Subject has had a prior colorectal resection for any reason other than sigmoid diverticular disease
  • Subject has had overt rectal bleeding, e.g. hematochezia or melena, within the previous 30 days. (Blood on toilet paper, after wiping, does not constitute rectal bleeding)
  • Subject has a diagnosis or personal history of any of the following high-risk conditions for colorectal cancer
    • Inflammatory bowel disease (IBD) including chronic ulcerative colitis (CUC) and Crohn's disease
    • 2 first-degree relatives who have been diagnosed with colon cancer. (Note: first-degree relatives include parents, siblings and offspring)
    • One first-degree relative with CRC diagnosed before the age of 60
  • Subject has a family history of
    • Familial adenomatous polyposis (also referred to as "FAP", including attenuated FAP)
    • Hereditary non-polyposis colorectal cancer syndrome (also referred to as "HNPCC" or "Lynch Syndrome")
    • Other hereditary cancer syndromes including but are not limited to Peutz-Jeghers Syndrome, MYH-Associated Polyposis (MAP), Gardner's Syndrome, Turcot's (or Crail's) Syndrome, Cowden's Syndrome, Juvenile Polyposis, Cronkhite-Canada Syndrome, Neurofibromatosis and Familial Hyperplastic Polyposis

Sedes participantes de Mayo Clinic

Los estatus de los estudios cambian con frecuencia. Comunícate con el equipo del estudio para obtener la información más actualizada acerca de la posibilidad de participar.

Sede de Mayo Clinic Estatus

Rochester, Minn.

Investigador principal de Mayo Clinic

Seth Sweetser, M.D.

Cerrado para la inscripción

More information

Publicaciones

Publications are currently not available
.
CLS-20205985

Mayo Clinic Footer